Recently, the Shanghai Center for Clinical Laboratory Quality Control released the "2025 Inter-Laboratory Quality Assessment Results Report for Plasma Microbial Cell-Free DNA Metagenomic High-Throughput Sequencing (Survey Project)". YunKang Group · Guangzhou DaAn Clinical Laboratory achieved excellent results in this EQA, once again confirming its technical stability and quality management level in the field of metagenomic next-generation sequencing (mNGS) for pathogenic microorganisms.

This mNGS EQA set multi-dimensional evaluation criteria. The assessment covered various pathogens including Gram-positive bacteria, Gram-negative bacteria, Candida, Cryptococcus, and DNA viruses, evaluating aspects such as false positives, false negatives, and detection robustness.

Results Report

Additionally, for complex interference scenarios such as hemolyzed samples, replicate samples, and serially diluted samples, the RPM ratio of each microbial detection result was required to fall within a specified range. In terms of detection sensitivity, laboratories were explicitly required to identify fungi at concentrations as low as 10 copies/mL, bacteria at 40 copies/mL, and viruses at 200 copies/mL. The overall assessment criteria posed high demands on detection accuracy and anti-interference capability.

YunKang Laboratory passed this EQA with high scores, relying on its mature technical system and standardized quality control processes. Its "YunZhiYuan - Metagenomic Next-Generation Sequencing (mNGS) for Pathogens" project can cover over 26,000 pathogen species and simultaneously detect resistance genes, providing reference for clinical medication. From sample reception, transportation, pre-processing, to DNA extraction, library construction, sequencing, and data analysis, each step follows standardized operating procedures, ensuring a complete workflow from sample receipt to report issuance within 24 hours, providing timely professional support for clinical diagnosis of critical and complex infections such as bloodstream infections and sepsis.

Previously, YunKang has participated for many consecutive years in EQAs organized by professional institutions such as the National Center for Clinical Laboratories and the Shanghai Center for Clinical Laboratory Quality Control, passing with excellent results each time. Behind these multiple authoritative recognitions is YunKang’s adherence to the service principles of "standardization, professionalism, and normalization" , as well as the result of its continuous investment in technical optimization and quality control.

As a key technology for diagnosing difficult and critical infectious diseases, the quality of mNGS testing directly affects clinical diagnosis and treatment direction as well as patient outcomes.

This high-score pass in the EQA not only recognizes YunKang’s current technical capabilities and service quality but also provides a reference for future service optimization. Going forward, YunKang will continue to refine its testing technology and improve its quality control system with rigorous standards, continuously enhancing the accuracy and efficiency of its testing services, providing reliable support for clinical diagnosis and treatment, and contributing to the improvement of infectious disease diagnosis.